Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
Abstract Insulin therapy often increases body weight and leads to visceral fat accumulation. Progression in diabetes is also associated with accelerated loss of muscle mass. Little is known about body composition changes in type 2 diabetes mellitus (T2DM) patients on insulin therapy who use sodium–g...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-21486-9 |
| _version_ | 1798030038062333952 |
|---|---|
| author | Yi-Hong Zeng Sung-Chen Liu Chun-Chuan Lee Fang-Ju Sun Jason J. Liu |
| author_facet | Yi-Hong Zeng Sung-Chen Liu Chun-Chuan Lee Fang-Ju Sun Jason J. Liu |
| author_sort | Yi-Hong Zeng |
| collection | DOAJ |
| description | Abstract Insulin therapy often increases body weight and leads to visceral fat accumulation. Progression in diabetes is also associated with accelerated loss of muscle mass. Little is known about body composition changes in type 2 diabetes mellitus (T2DM) patients on insulin therapy who use sodium–glucose cotransporter-2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors. This study examined the effect of 25 mg of empagliflozin compared with 5 mg of linagliptin for 24 weeks on body weight and body composition in patients with T2DM on premixed insulin. Body composition was assessed with bioelectrical impedance analysis. The mean difference between the linagliptin and empagliflozin groups in terms of mean body weight change from baseline to 24 weeks was − 1.80 kg (95% CI − 2.57, − 1.03). Empagliflozin also significantly reduced muscle mass (− 1.39 kg, 95% CI − 2.49, − 0.29) and total body water (− 1.07 kg, 95% CI − 1.88, − 0.27) compared with linagliptin. Compared to linagliptin, empagliflozin decreased body fat mass more from baseline to week 24, but this was not significant (− 0.31 kg, 95% CI − 1.51, 0.90). Further research on insulin-treated T2DM patients is necessary to investigate the long-term effects of SGLT2 and DPP4 inhibitors on body composition, as well as their effects on muscle strength and physical function. Trial registration: ClinicalTrials.gov no. NCT03458715, registration date: March 8, 2018. |
| first_indexed | 2024-04-11T19:33:53Z |
| format | Article |
| id | doaj.art-299d6d5954f848f28805d4f185403796 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T19:33:53Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-299d6d5954f848f28805d4f1854037962022-12-22T04:06:54ZengNature PortfolioScientific Reports2045-23222022-10-011211510.1038/s41598-022-21486-9Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulinYi-Hong Zeng0Sung-Chen Liu1Chun-Chuan Lee2Fang-Ju Sun3Jason J. Liu4Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial HospitalDivision of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial HospitalDepartment of Medical Research, MacKay Memorial HospitalInstitute of Public Health, National Yang Ming Chiao Tung UniversityAbstract Insulin therapy often increases body weight and leads to visceral fat accumulation. Progression in diabetes is also associated with accelerated loss of muscle mass. Little is known about body composition changes in type 2 diabetes mellitus (T2DM) patients on insulin therapy who use sodium–glucose cotransporter-2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors. This study examined the effect of 25 mg of empagliflozin compared with 5 mg of linagliptin for 24 weeks on body weight and body composition in patients with T2DM on premixed insulin. Body composition was assessed with bioelectrical impedance analysis. The mean difference between the linagliptin and empagliflozin groups in terms of mean body weight change from baseline to 24 weeks was − 1.80 kg (95% CI − 2.57, − 1.03). Empagliflozin also significantly reduced muscle mass (− 1.39 kg, 95% CI − 2.49, − 0.29) and total body water (− 1.07 kg, 95% CI − 1.88, − 0.27) compared with linagliptin. Compared to linagliptin, empagliflozin decreased body fat mass more from baseline to week 24, but this was not significant (− 0.31 kg, 95% CI − 1.51, 0.90). Further research on insulin-treated T2DM patients is necessary to investigate the long-term effects of SGLT2 and DPP4 inhibitors on body composition, as well as their effects on muscle strength and physical function. Trial registration: ClinicalTrials.gov no. NCT03458715, registration date: March 8, 2018.https://doi.org/10.1038/s41598-022-21486-9 |
| spellingShingle | Yi-Hong Zeng Sung-Chen Liu Chun-Chuan Lee Fang-Ju Sun Jason J. Liu Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin Scientific Reports |
| title | Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin |
| title_full | Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin |
| title_fullStr | Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin |
| title_full_unstemmed | Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin |
| title_short | Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin |
| title_sort | effect of empagliflozin versus linagliptin on body composition in asian patients with type 2 diabetes treated with premixed insulin |
| url | https://doi.org/10.1038/s41598-022-21486-9 |
| work_keys_str_mv | AT yihongzeng effectofempagliflozinversuslinagliptinonbodycompositioninasianpatientswithtype2diabetestreatedwithpremixedinsulin AT sungchenliu effectofempagliflozinversuslinagliptinonbodycompositioninasianpatientswithtype2diabetestreatedwithpremixedinsulin AT chunchuanlee effectofempagliflozinversuslinagliptinonbodycompositioninasianpatientswithtype2diabetestreatedwithpremixedinsulin AT fangjusun effectofempagliflozinversuslinagliptinonbodycompositioninasianpatientswithtype2diabetestreatedwithpremixedinsulin AT jasonjliu effectofempagliflozinversuslinagliptinonbodycompositioninasianpatientswithtype2diabetestreatedwithpremixedinsulin |